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comprised populations that differ 
genetically in their response 
to the environment at spatial 
scales of around 600–800 km, 
undetected by microsatellite 
DNA variations. They caught 
cod from four populations 
within the Atlantic and looked at 
larval growth in the laboratory. 
Among all four populations, 
growth increased with food 
supply and temperature but the 
influence of changes in food 
and temperature on survival 
differed between warm- and 
cold-water populations, the 
researchers found. The results 
imply that Atlantic cod do not 
respond as a whole to similar 
changes in the environment 
in a similar manner. Increased 
water temperature, for example, 
is predicted to have a positive 
influence on the larval survival of 
warm-water populations. But the 
interactive effect of temperature 
and food had different effects on 
survival amongst the different 
populations.
The team found that, at lower 
temperatures, survival of the cod 
from warmer waters increased 
with food supply, whereas 
growth of cold-water-derived 
cod was unaffected by increased 
food. The authors believe their 
data reveal “significant genetic 
differences among populations 
of Atlantic cod at a spatial scale 
at which disjunctions in gene 
flow were not detectable using 
traditional population genetics 
markers.”
The collapse of many of the 
world’s fisheries underscores 
a pressing need to study 
the adaptive variation in 
commercially exploited 
marine species with the aim of 
establishing recovery strategies 
at biological meaningful and 
genetically relevant spatial 
scales, the researchers write.  
“In this regard this work 
underscores the merit in 
undertaking experiments in 
conjunction with studies of 
population structure based 
solely on allelic variability, 
particularly for genes thought 
to be under natural selection.” 
From the results of this research, 
restocking fisheries may require 
a very particular type of fish.Q & A
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What made you study biology? 
In the early 1960s nothing was 
taught in school about the then new 
‘molecular biology’, but the BBC ran 
programmes on Sunday morning 
where scientists like John Kendrew 
and John Maynard Smith showed 
that something exciting was afoot. 
Reading into such extra- curricular 
biology got me interested in 
DNA and, despite a relatively 
undistinguished academic record, 
I managed to get into Sussex, then 
a brand new university. Luckily, 
Maynard Smith was there and so 
was Asher Korner, whose teaching 
really struck a chord. It wasn’t until 
late in my undergraduate days that 
research seemed a serious option. 
I got a place with Max Birnstiel in 
Edinburgh, the first laboratory to 
study an isolated gene. In those 
pre-cloning days, genes had to be 
purified the hard way by physical 
methods: equilibrium buoyant 
density ultracentrifugation in 
caesium chloride solution to be 
precise. Only repetitive genes like 
the ribosomal RNA genes (rDNA) 
were abundant enough for this to 
work. I chose to look at ribosomal 
gene amplification in Xenopus 
oocytes and continued this at 
Yale in the laboratory of Joe Gall, 
a discoverer of the amplification 
phenomenon. We helped to prove 
that a ‘rolling circle’ DNA replication 
mechanism was at work.
Are you now or have you ever 
been an ‘epigeneticist’? I did 
my PhD in the 1960s in the ‘MRC 
Epigenetics Research Group’ which was christened by its director, C.H. 
Waddington. For Wad, epigenetics 
described the processes by which 
the genotype gave rise to the 
phenotype; in other words, the 
molecular biology of development. 
To be honest, the word didn’t 
catch on, which is why today’s 
developmental biologists don’t call 
themselves epigeneticists. Instead 
it has transmogrified into a word 
that either describes non- genetic 
inheritance or the biology of 
chromatin marks, or both. I accept 
that working on DNA methylation 
makes me an epigeneticist. In 
the final analysis, though, the 
naming of biological processes is 
inconsequential; we just want to 
know how they work.
Has chance influenced your 
research? Naturally. A particular 
stroke of luck occurred in 1975 
during a postdoctoral spell 
in Zurich. Hamilton Smith, a 
discoverer of type II restriction 
endonucleases, came through on 
sabbatical and, to get his hand 
in, made a massive amount of 
the enzyme HpaII. I had some 
chromosomal rDNA from blood and 
some amplified extrachromosomal 
rDNA from oocytes, so tried this 
new-fangled restriction technology 
on both. The amplified rDNA 
was minced to small pieces, 
but the blood rDNA was uncut. 
Don Brown and Igor Dawid had 
previously shown that the difference 
between these two was cytosine 
methylation, so it was obvious 
restriction enzymes could be used 
to map methylated sites.
Chance also led my laboratory to 
work on MeCP2, which has turned 
out to be an intriguing protein in 
brain development. While at the 
Institute for Molecular Pathology 
in Vienna, we identified proteins 
that bound to methylated but not 
unmethylated DNA. The easiest to 
purify was MeCP2, so we focused 
more on that one and found it to 
be a transcriptional repressor. 
Unknown to me, Andreas Rett 
was also working in Vienna at that 
time (1990), but it wasn’t until ten 
years later that Huda Zoghbi and 
colleagues discovered that MECP2 
was in fact the gene mutated in 
the disorder named after him, Rett 
Syndrome. By this time we had 
some useful clues about what 
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produced! And what a valuable 
lesson it was. 
There are some rules that help, 
I suppose: short sentences, the 
active voice, as few technical and 
compound words as possible, 
and so on. I used to write by hand, 
read (out loud) into a tape recorder, 
re-read the typed outcome, throw 
away, read a page of Nietzsche, and 
start again. But in my experience 
these rules and methods are only 
the starting point, and some rather 
more ‘interactive’ instruction is 
required. Watson applied the 
following method (at least to me): 
my finely honed draft was sailed 
back across the table accompanied 
by an eyebrow-push-up-grimace 
and the word: “Unreadable”. 
Reminds me of my all-time most 
memorable violin lesson. I walked 
into the home of the Russian 
virtuoso with whom I was studying 
and he said, deadpan: “I see you 
are smiling. Why are you smiling? If 
I played like you I wouldn’t smile.” 
We call this the 
boulder- in- the- road teaching 
method, and it is not so uncommon 
in music, especially among the 
great Russians. A friend of mine 
tells me about her friend who 
went to study with Heifetz — yes, 
Jascha Heifetz. The first week 
he told Heifetz he would play the 
Sibelius Concerto, and JH said 
“We’ll see about that.” The student 
got through the first page before 
being sent home “to practice”. 
Upon repeated attempts he never 
got past the first page until, the 
last day, JH let him play the whole 
thing and then said: “It’s as I 
thought: you can’t play the Sibelius 
Concerto. Next.” Before being 
too harsh on Jascha, recall the 
story about Max Delbrück — the 
very Max I mentioned in my last 
communiqué [1]. It is said that 
Max returned a manuscript, torn to 
pieces, along with a note that said: 
“Please switch fields.”
Al Hershey didn’t bother to tear 
up my manuscript. I wrote a 20 
page paper for him and got it back 
with most lines crossed out and 
the occasional  phrase circled and 
marked “Good”. So I rewrote and 
rewrote and it came back with not 
a mark on the first page! Not a 
mark on the second! Then the third 
page: a line through the middle, a 
penciled-in “START HERE”, and 
On learning to 
write
Mark Ptashne
I learn from Bill Bryson in his fine 
“A Short History of Everything” 
that obscure scientific writing 
has a well- established history. 
Newton wrote impenetrably to 
keep tourists out; the geologist 
Hutton, with profound things 
to say, wrote obscurely, and to 
his detriment, because he was 
incapable of writing a coherent 
English sentence. Is there a third, 
perhaps more modern, category 
of obscurantism? Let’s face it: day 
by day molecular biology can be 
tedious stuff indeed. Surely there 
must be some better world — one 
in which we solve meta-problems 
rather than quotidian ones. The 
public (including us) wants what 
we might call a ‘leapfrogging’: 
there must be a way, or ways, to 
describe and deduce in general 
rather than in particular. In that 
breathless atmosphere, obscurity 
can be useful to the writer, 
ignored or encouraged by editors, 
embraced by administrators and 
deep pockets. 
Lets put these dark thoughts 
aside. Most of us, I’ll assume, 
do want to write clearly, but how 
does one learn to do it? Our brains 
(some anyway) work in fits and 
starts — this reminds me of that, 
that reminds me of this, do you 
know the joke about Sam, and so 
on. But standard scientific writing 
won’t allow that to be transferred 
to the page. Some people think 
the problem must be tackled on 
a grand scale: the student is told 
to present and defend, in writing, 
an experimental plan to solve an 
outstanding problem outside his 
main area of interest. Wow — a 
job for JBS Haldane, but not for 
most of us. As a graduate student, 
I assisted in a course taught by 
Jim Watson at Harvard. One of 
Watson’s requirements was that 
each student write a three page 
paper on something, anything, 
related to the course. Oh what 
masterpieces of indirection were 
My Wordthe protein might be doing. I like to think that this is an example of 
blue skies research turning out to 
be practically useful, although it 
has yet to lead to therapy for this 
debilitating neurological disorder.
What are the most exciting areas 
for future research? It is possible 
to forget that we live in the golden 
age of biology and will do for some 
time to come. Genome projects 
have given us a list of components 
but told us nothing about how 
they work to make life. The next 
century of biomedical research 
will be required to fully exploit 
this resource. Nominating areas 
of future research excitement is 
almost always a futile exercise 
because, thank goodness, we are 
constantly being surprised. This 
unpredictability is precisely why 
curiosity-driven research is such 
a vital part of the future. In spite 
of the uncertainty, an obvious 
area to watch closely is the brain. 
Here ignorance is huge and the 
possibility of surprising discoveries 
correspondingly great.
Ambitions? Having presided over 
my share of transient transfections 
using permanent cell lines, I have 
finally come to accept the truism 
that such cells are biologically 
eccentric entities with limited 
relevance to life as we know it. 
Neurons, on the other hand, are 
‘real’ cells that are huge and can 
preserve their complex structure 
and connectivity in the nervous 
system for decades. As yet 
we know little about how their 
molecular biology makes this 
possible. It was amazing to find 
recently that mice with severe 
brain malfunction due to MeCP2-
deficiency could be essentially 
cured by putting the protein back. 
Like others, we had assumed 
that such “neurodevelopmental” 
defects would be irreversible. It 
looks as though MeCP2 acts as a 
maintenance factor that fixes gene 
expression programmes in different 
types of mature neurons. Now this 
idea needs testing.
The Wellcome Trust Centre for Cell 
Biology, School of Biological Sciences, 
University of Edinburgh, Michael Swann 
Building, Mayfield Road, Edinburgh 
EH9 3JR, UK.  
E-mail: a.bird@ed.ac.uk
